259 related articles for article (PubMed ID: 17306728)
1. Buprenorphine for acute heroin detoxification: diffusion of research into practice.
Kovas AE; McFarland BH; McCarty DJ; Boverman JF; Thayer JA
J Subst Abuse Treat; 2007 Mar; 32(2):199-206. PubMed ID: 17306728
[TBL] [Abstract][Full Text] [Related]
2. Well-being, psychosocial factors, and side-effects among heroin-dependent inpatients after detoxification using buprenorphine versus clonidine.
Ponizovsky AM; Grinshpoon A; Margolis A; Cohen R; Rosca P
Addict Behav; 2006 Nov; 31(11):2002-13. PubMed ID: 16524668
[TBL] [Abstract][Full Text] [Related]
3. Using buprenorphine to facilitate entry into residential therapeutic community rehabilitation.
Collins ED; Horton T; Reinke K; Amass L; Nunes EV
J Subst Abuse Treat; 2007 Mar; 32(2):167-75. PubMed ID: 17306725
[TBL] [Abstract][Full Text] [Related]
4. Tramadol versus buprenorphine for the management of acute heroin withdrawal: a retrospective matched cohort controlled study.
Threlkeld M; Parran TV; Adelman CA; Grey SF; Yu J
Am J Addict; 2006; 15(2):186-91. PubMed ID: 16595358
[TBL] [Abstract][Full Text] [Related]
5. Outpatient versus inpatient opioid detoxification: a randomized controlled trial.
Day E; Strang J
J Subst Abuse Treat; 2011 Jan; 40(1):56-66. PubMed ID: 21036514
[TBL] [Abstract][Full Text] [Related]
6. A double-blind, double-dummy, randomized, prospective pilot study of the partial mu opiate agonist, buprenorphine, for acute detoxification from heroin.
Oreskovich MR; Saxon AJ; Ellis ML; Malte CA; Reoux JP; Knox PC
Drug Alcohol Depend; 2005 Jan; 77(1):71-9. PubMed ID: 15607843
[TBL] [Abstract][Full Text] [Related]
7. A cost-effectiveness analysis of buprenorphine-assisted heroin withdrawal.
Doran CM; Shanahan M; Bell J; Gibson A
Drug Alcohol Rev; 2004 Jun; 23(2):171-5. PubMed ID: 15370023
[TBL] [Abstract][Full Text] [Related]
8. Buprenorphine maintenance treatment in a primary care setting: outcomes at 1 year.
Soeffing JM; Martin LD; Fingerhood MI; Jasinski DR; Rastegar DA
J Subst Abuse Treat; 2009 Dec; 37(4):426-30. PubMed ID: 19553061
[TBL] [Abstract][Full Text] [Related]
9. The characteristics of heroin users entering treatment: findings from the Australian treatment outcome study (ATOS).
Ross J; Teesson M; Darke S; Lynskey M; Ali R; Ritter A; Cooke R
Drug Alcohol Rev; 2005 Sep; 24(5):411-8. PubMed ID: 16298835
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of a transdermal buprenorphine formulation in opioid detoxification.
Lanier RK; Umbricht A; Harrison JA; Nuwayser ES; Bigelow GE
Addiction; 2007 Oct; 102(10):1648-56. PubMed ID: 17854341
[TBL] [Abstract][Full Text] [Related]
11. Anesthesia-assisted vs buprenorphine- or clonidine-assisted heroin detoxification and naltrexone induction: a randomized trial.
Collins ED; Kleber HD; Whittington RA; Heitler NE
JAMA; 2005 Aug; 294(8):903-13. PubMed ID: 16118380
[TBL] [Abstract][Full Text] [Related]
12. Opioid detoxification with buprenorphine, clonidine, or methadone in hospitalized heroin-dependent patients with HIV infection.
Umbricht A; Hoover DR; Tucker MJ; Leslie JM; Chaisson RE; Preston KL
Drug Alcohol Depend; 2003 Apr; 69(3):263-72. PubMed ID: 12633912
[TBL] [Abstract][Full Text] [Related]
13. Rapid detoxification of heroin dependence by buprenorphine.
Liu ZM; Cai ZJ; Wang XP; Ge Y; Li CM
Zhongguo Yao Li Xue Bao; 1997 Mar; 18(2):112-4. PubMed ID: 10072959
[TBL] [Abstract][Full Text] [Related]
14. One year outcomes for heroin dependence: findings from the Australian Treatment Outcome Study (ATOS).
Teesson M; Ross J; Darke S; Lynskey M; Ali R; Ritter A; Cooke R
Drug Alcohol Depend; 2006 Jun; 83(2):174-80. PubMed ID: 16343809
[TBL] [Abstract][Full Text] [Related]
15. Use of qigong therapy in the detoxification of heroin addicts.
Li M; Chen K; Mo Z
Altern Ther Health Med; 2002; 8(1):50-4, 56-9. PubMed ID: 11795622
[TBL] [Abstract][Full Text] [Related]
16. Prospective randomised comparative study of the effect of buprenorphine, methadone and heroin on the course of pregnancy, birthweight of newborns, early postpartum adaptation and course of the neonatal abstinence syndrome (NAS) in women followed up in the outpatient department.
Binder T; Vavrinková B
Neuro Endocrinol Lett; 2008 Feb; 29(1):80-6. PubMed ID: 18283247
[TBL] [Abstract][Full Text] [Related]
17. A comparison of buprenorphine and lofexidine for community opiate detoxification: results from a randomized controlled trial.
Raistrick D; West D; Finnegan O; Thistlethwaite G; Brearley R; Banbery J
Addiction; 2005 Dec; 100(12):1860-7. PubMed ID: 16367987
[TBL] [Abstract][Full Text] [Related]
18. Behavioral drug and HIV risk reduction counseling (BDRC) with abstinence-contingent take-home buprenorphine: a pilot randomized clinical trial.
Chawarski MC; Mazlan M; Schottenfeld RS
Drug Alcohol Depend; 2008 Apr; 94(1-3):281-4. PubMed ID: 18164145
[TBL] [Abstract][Full Text] [Related]
19. Client and counselor attitudes toward the use of medications for treatment of opioid dependence.
Rieckmann T; Daley M; Fuller BE; Thomas CP; McCarty D
J Subst Abuse Treat; 2007 Mar; 32(2):207-15. PubMed ID: 17306729
[TBL] [Abstract][Full Text] [Related]
20. Relationship between plasma cortisol levels, withdrawal symptoms and craving in abstinent and treated heroin addicts.
Nava F; Caldiroli E; Premi S; Lucchini A
J Addict Dis; 2006; 25(2):9-16. PubMed ID: 16785214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
